Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,582 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06342440Recruiting
Early detection of colon cancer and advanced polyps
This study aims to find colorectal cancer and advanced polyps (adenomas) earlier by looking at blood samples. Researchers hope a simple blood test might one day help detect colon cancer before it spreads.
Monrovia, CaliforniaAges 18 years+ - NCT06342401Recruiting
Early onset colorectal cancer detection study
This study aims to improve detection of colorectal cancer in people diagnosed before age 50. It compares samples from patients with cancer to those without to find new early detection methods.
Duarte, CaliforniaAges 18–50 - NCT06043713RecruitingPhase 1
T-cell therapy for KRAS G12V solid tumors
This trial tests a personalized T-cell therapy designed to recognize and attack cancer cells with a specific KRAS G12V mutation. It is for people with metastatic solid tumors that have this mutation and a specific immune type (HLA-A*11:01).
Seattle, WashingtonAges 18 years+ - NCT07682883Enrolling by invitation
Mouth screening to prevent oral cancer
This study checks how well routine mouth exams can find early signs of oral cancer. It is for adults who do not already have a condition called OPMD (a mouth problem that can lead to cancer) and are not being treated for it.
Warsaw, Masovian VoivodeshipAges 18 years+ - NCT07337525RecruitingPhase 1
First study of PLT012 in advanced solid tumors
This trial tests a new drug called PLT012 for people with advanced solid tumors. It is the first study in humans, so doctors will see if the drug is safe and how the body handles it.
Los Angeles, CaliforniaAges 18 years+ - NCT06996249Recruiting
Thoracic cancer data collection study
This study collects medical information from people with suspected or confirmed thoracic cancer. The goal is to learn more about these cancers and improve future care.
Ede, GelderlandAges 18 years+ - NCT06713369RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests an experimental drug called Saruparib in people with advanced solid tumors that haven't responded to standard treatments. The study will see how the drug is absorbed, distributed, and eliminated from the body.
LiverpoolAges 18 years+ - NCT06714903Recruiting
Gut bacteria and immunotherapy for advanced colon cancer
This study looks at how the bacteria in your gut might affect how well immunotherapy works for advanced colorectal cancer that has spread. It aims to find out if certain gut bacteria can help make treatment more effective.
Changchun, JilinAges 35–75 - NCT06715839Recruiting
Digestive cancer imaging study with targeted antibodies
This trial uses a special imaging test (PET scan) to find digestive system cancers. It uses molecules that attach to cancer cells so they light up on the scan, which may help doctors see tumors more clearly.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06717113RecruitingEarly Phase 1
A new imaging test for multiple myeloma
This trial tests a special imaging dye that targets a protein called BCMA on multiple myeloma cells. It may help doctors see and diagnose the disease more clearly during bone marrow or tissue biopsies.
Beijing, Beijing MunicipalityAges 18–80 - NCT06720324RecruitingPhase 1/Phase 2
CD7-targeted CAR-T therapy for relapsed blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a specific marker called CD7 on blood cancer cells. It is for people whose blood cancer has not responded to other treatments or has come back after treatment.
Wuhan, HubeiAges 3–75 - NCT06726642Recruiting
Blood test study for people with inherited cancer risk
This study looks for DNA fragments in blood of people with certain inherited cancer syndromes. It may help find cancer earlier or guide better monitoring. You would give blood samples every 4 months (if in the experimental group).
Vancouver, British ColumbiaAges Up to 90 years - NCT06731504RecruitingEarly Phase 1
Abatacept to prevent graft-versus-host disease after omidubicel stem cell transplant
This trial tests whether adding abatacept to standard care can reduce graft-versus-host disease (a condition where donor cells attack your body) after a stem cell transplant using a special cord blood product called omidubicel. It is for adults with blood cancers who have a suitable cord blood unit available.
Durham, North CarolinaAges 18 years+ - NCT06734572RecruitingEarly Phase 1
PET/CT imaging study for solid tumors
This study uses a special PET/CT scan to see how a new imaging agent (18F-FAPIBiotin) spreads in the body and how much radiation it gives off. It's for people with confirmed solid tumors to help make future imaging more accurate.
Fuzhou, FujianAges 18–80 - NCT06737081RecruitingPhase 2
Study of an experimental anemia treatment for chemotherapy patients
This study tests a new medication (SAL-0951) for treating low red blood cell counts (anemia) caused by chemotherapy in people with certain types of cancer that are not curable. It may help improve energy and reduce the need for blood transfusions.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06756152RecruitingPhase 2/Phase 3
Preventing GVHD after transplant for blood cancers in children and young adults
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
MoscowAges 1 day–21 years - NCT06756321RecruitingEarly Phase 1
CAR T-cell therapy for relapsed blood cancers
This study tests a new type of therapy called CAR T-cells for people with blood cancers that have returned or not responded to standard treatments. CAR T-cells are made from your own immune cells and are trained to find and kill cancer cells.
Nantong, JiangsuAges 18–70 - NCT06756451RecruitingPhase 1
Experimental drug for relapsed or refractory AML
This trial tests an experimental drug (RJK-RT2831) for people with AML that has not responded to standard treatments. The drug targets two markers on leukemia cells (CD33 and CD123). The study is early-stage, aiming to find the right dose and check safety.
Hefei, AnhuiAges 18–74 - NCT06760923Recruiting
Urine test for ovarian cancer detection and tracking
This study looks at proteins in urine to help find ovarian cancer earlier and track how the disease changes. It aims to provide a non-invasive way to tell the difference between benign and malignant pelvic masses.
Changsha, HunanAges 18 years+ - NCT06765876RecruitingEarly Phase 1
CAR T-cell therapy for CD123+ blood cancers
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called CD123 on cancer cells. It is for people with certain blood cancers (AML, MDS-IB2, BPDCN, or ALL) that have come back or not responded to other treatments.
PragueAges 18–70 - NCT06769152RecruitingPhase 2
HLX43 for advanced gynecological cancers
This trial tests a new drug, HLX43, that targets a protein called PD-L1 found on some cancer cells. It is for people with advanced cervical or ovarian cancer that has stopped responding to standard treatments.
Ji'nan, ShandongAges 18–75 - NCT06778187RecruitingPhase 2
Oral arsenic therapy for TP53-mutated blood cancers
This trial tests a combination of oral medications, including arsenic trioxide, venetoclax, and a chemotherapy agent (azacitidine or decitabine), for people with certain blood cancers (AML, MDS, or CMML) that have a TP53 gene mutation. The goal is to see if this pill-based treatment can help control the cancer.
Hong KongAges 18 years+ - NCT06778382RecruitingPhase 2
Delaying treatment after destroying lung spots from colorectal cancer
This trial tests if it's safe to wait before starting full-body therapy after treating a small number of lung tumors (5 or fewer) in people whose colorectal cancer had been gone for at least 6 months. You would first get local treatments like surgery or radiation to destroy the lung spots, then delay additional cancer drugs to see how you do.
Jinan, ShandongAges 18–75 - NCT06778512Recruiting
Lung nodule study: using CT scans and breathing tests
This study looks at lung nodules found on CT scans. Researchers will collect data from your breathing tests and CT scans to better understand how these nodules relate to lung cancer.
Guangzhou, GuangdongAges 18–75
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,582 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.